Literature DB >> 28571489

Thioredoxin-1, chemokine (C-X-C motif) ligand-9 and interferon-γ expression in the neoplastic cells and macrophages of Hodgkin lymphoma: clinicopathologic correlations and potential prognostic implications.

Theodoros P Vassilakopoulos1, Georgia Levidou2, Vassilis Milionis2, Sylvia Hartmann3, Eleftheria Lakiotaki2, Athanasia Sepsa2, Irene Thymara2, Panagiota Ntailiani2, Kallirroi Spanou2, Maria K Angelopoulou1, Marina P Siakantaris1, Maria Moschogiannis4, Gerassimos A Pangalis4, Panayiotis Panayiotidis3, Kostas Konstantopoulos3, Efstratios Patsouris2, Martin-Leo Hansmann3, Penelope Korkolopoulou2.   

Abstract

Expression of thioredoxin-1 (TXN) and CXCL9 is not restricted to THRLBCL macrophages, but may be observed in histiocytes and neoplastic (HRS) cells of EBV + mixed cellularity (MC) classical Hodgkin lymphoma (cHL) and nodular lymphocyte predominant HL. We aimed to validate and extend the above observations in 174 cHL patients evaluating the immunohistochemical expression of TXN, CXCL9 and IFN-γ. HRS-cell CXCL9 expression was higher in latent membrane protein-1 (LMP1)+, MC and Stage IV. TXN and CXCL9 expression by cHL histiocytes was more frequent in LMP1+, MC and older patients (only for CXCL9). TXN expression by HRS cells (≥80%) was independently associated with better failure-free survival. In conclusion, markers of TCHRLBCL histiocytes (TXN, CXCL9), as well as IFN-γ are also expressed by histiocyte subsets and neoplastic cells of cHL. The expression of some of them is more prominent in EBV + MC, but not restricted to this subtype. The prognostic implication of TXN needs further evaluation.

Entities:  

Keywords:  CXCL9; Epstein–Barr; Hodgkin lymphoma; Thioredoxin; immunohistochemistry; interferon-γ

Mesh:

Substances:

Year:  2017        PMID: 28571489     DOI: 10.1080/10428194.2017.1289520

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma.

Authors:  Jennifer E Agrusa; Brooks P Scull; Harshal A Abhyankar; Howard Lin; Nmazuo W Ozuah; Rikhia Chakraborty; Olive S Eckstein; Nitya Gulati; Elmoataz Abdel Fattah; Nader K El-Mallawany; Rayne H Rouce; ZoAnn E Dreyer; Julienne Brackett; Judith F Margolin; Joseph Lubega; Terzah M Horton; Catherine M Bollard; M Monica Gramatges; Kala Y Kamdar; Kenneth L McClain; Tsz-Kwong Man; Carl E Allen
Journal:  Cancers (Basel)       Date:  2020-12-02       Impact factor: 6.639

2.  Laying the groundwork for the Biobank of Rare Malignant Neoplasms at the service of the Hellenic Network of Precision Medicine on Cancer.

Authors:  Dimitrios S Kanakoglou; Andromachi Pampalou; Dimitrios M Vrachnos; Eleni A Karatrasoglou; Dionysia N Zouki; Emmanouil Dimonitsas; Alexia Klonou; Georgia Kokla; Varvara Theologi; Errieta Christofidou; Stratigoula Sakellariou; Eleftheria Lakiotaki; Christina Piperi; Penelope Korkolopoulou
Journal:  Int J Oncol       Date:  2022-02-16       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.